Sonoma Pharmaceuticals, Inc.
SNOAUS売上高
$20M
百万USD
営業利益
$-2M
百万USD
純利益
$-3M
百万USD
ROE
-102.6%
最新FY
EPS
$-1.89
USD / 株
配当
-
USD / 株
業績推移
収益性
キャッシュフロー
財務状況
四半期業績
| 年度 | 期 | 売上高 | 純利益 | EPS |
|---|---|---|---|---|
| FY2021 | Q1 | $6M | $0M | $0.13 |
| FY2021 | Q2 | $6M | $0M | $0.06 |
| FY2021 | Q3 | $5M | $-1M | - |
| FY2021 | FY | $19M | $-4M | - |
| FY2022 | Q1 | $4M | $-1M | $-0.52 |
| FY2022 | Q2 | $4M | $-0M | $-0.04 |
| FY2022 | Q3 | $3M | $-1M | $-0.31 |
| FY2022 | FY | $13M | $-5M | - |
| FY2023 | Q1 | $4M | $-1M | $-0.29 |
| FY2023 | Q2 | $3M | $-1M | $-0.33 |
| FY2023 | Q3 | $3M | $-2M | $-0.62 |
| FY2023 | FY | $13M | $-5M | $-1.52 |
| FY2024 | Q1 | $3M | $-1M | $-0.29 |
| FY2024 | Q2 | $3M | $-1M | $-0.29 |
| FY2024 | Q3 | $3M | $-1M | $-0.08 |
| FY2024 | FY | $13M | $-5M | $-0.53 |
| FY2025 | Q1 | $3M | $-1M | $-0.07 |
| FY2025 | Q2 | $4M | $-1M | $-0.59 |
| FY2025 | Q3 | $4M | $-1M | $-0.63 |
| FY2025 | FY | $14M | $-3M | $-2.79 |
| FY2026 | Q1 | $4M | $-1M | $-0.76 |
| FY2026 | Q2 | $6M | $-1M | $-0.32 |
| FY2026 | Q3 | $4M | $-1M | $-0.48 |
| FY2026 | FY | $20M | $-3M | $-1.89 |
財務データ
| 指標 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 売上高 | - | - | - | - | $19M | $19M | $13M | $13M | $13M | $14M | $20M |
| 営業利益 | $-10M | $-13M | $-14M | $-11M | $-7M | $-3M | $-6M | $-5M | $-5M | $-4M | $-2M |
| 純利益 | $-10M | $9M | $-14M | $-12M | $-3M | $-4M | $-5M | $-5M | $-5M | $-3M | $-3M |
| 総資産 | $14M | $25M | $19M | $14M | $15M | $15M | $19M | $16M | $15M | $14M | $14M |
| 純資産 | - | - | - | - | - | - | - | - | - | - | - |
| 自己資本 | $10M | $21M | $15M | $10M | $9M | $5M | $9M | $8M | $6M | $4M | $3M |
| 営業CF | - | - | - | - | $-5M | $-3M | $-4M | $-6M | $-2M | $-0M | $-4M |
| EPS | - | - | - | - | - | - | - | $-1.52 | $-0.53 | $-2.79 | $-1.89 |
| BPS | $0.48 | $4.98 | $2.39 | $7.89 | $4.42 | $2.56 | $2.80 | $1.61 | $0.33 | $2.69 | $0.65 |
| ROE | -100.2% | 43.3% | -93.5% | -112.5% | -33.8% | -73.7% | -58.5% | -64.6% | -78.8% | -78.4% | -102.6% |